Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2020
- Source ID
- 10.1016/j.jaad.2019.10.034
Entities
People
- Bronwen E Shaw
- David Buchbinder
- Elizabeth K. Cahoon
- Eric A. Engels
- Heather R Tecca
- Lindsay M. Morton
- Margaret A. Tucker
- Mary E. Flowers
- Megan M. Herr
- Minoo Battiwalla
- Rochelle E. Curtis
- Ruta Brazauskas
Organizations
- Actinium Pharmaceuticals (United States)
- Amgen
- Angiocrine Bioscience (United States)
- Astellas Pharma (United States)
- AstraZeneca (United States)
- Atara Biotherapeutics, Inc.
- Celgene
- Chiron Corporation
- Fred Hutchinson Cancer Center
- Genzyme
- Gilead Sciences
- Health Resources and Services Administration
- Janssen Scientific Affairs (United States)
- Jazz Pharmaceuticals
- Karyopharm Therapeutics (United States)
- Kite Pharma
- Medical College of Wisconsin
- Meso Scale Diagnostics (United States)
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Otsuka Pharmaceutical
- Patient-Centered Outcomes Research Institute
- Pfizer
- Seagen
- Shire plc
- Spectrum Pharmaceuticals
- St. Baldrick's Foundation
- Swedish Orphan Biovitrum
- Takeda Oncology
- United States Department of Health and Human Services
- United States Public Health Service
- University of Minnesota